Sunday 11 October 2026 Export all EQ data to Excel Powerpack

Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.

1.41 0.03 −2.08%
Market cap
$91.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.75
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.85 10.58 18.62 23.40
Net Debt/EBITDA
7.28 7.69 10.98 11.15
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.13) (0.06) (0.04) (0.04)
Book value per Share
0.47 0.50 0.62 0.50
Free Cash Flow
(8.43) (3.16) (4.30) (4.18)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates